Sutro Biopharma scaled up its cell-free protein synthesis (CFPS) platform, XpressCF, to 4,500 L GMP manufacturing at Boehringer Ingelheim’s facility in Vienna, supporting production of Sutro’s antibody-drug conjugate luveltamab tazevibulin (luvelta) for cancer, marking the first large-scale commercial validation of CFPS by a third-party CDMO.
The global Cell-free Protein Synthesis (CFPS) Market continues to demonstrate strong momentum, driven by growing demand for efficient, scalable, and flexible protein production technologies. Valued at US$203.9 million in 2024, the market expanded to US$217.2 million in 2025 and is expected to reach US$308.9 million by 2030, advancing at a CAGR of 7.3%. This growth reflects a rapid shift toward cell-free systems for producing complex, toxic, or unstable proteins that are difficult to express using conventional cell-based methods.
As biopharmaceutical development, synthetic biology, and advanced diagnostics accelerate worldwide, CFPS platforms are increasingly recognized for their ability to deliver fast, controlled, and customizable protein synthesis without relying on living cells. These advantages are fueling widespread adoption across drug discovery, vaccine production, enzyme engineering, biosensor development, and academic research.
Download PDF Brochure
Key Growth Drivers Shaping the Cell-free Protein Synthesis Market
* Rising Need for Efficient Production of Toxic and Challenging Proteins
Traditional in vivo expression systems often face limitations when producing membrane-bound, aggregation-prone, or cytotoxic proteins. CFPS bypasses these constraints by eliminating the need to maintain living cells, enabling rapid synthesis and functional analysis. This unique capability makes CFPS a preferred technology for complex protein engineering and high-value therapeutic research.
* Integration of AI and Machine Learning
AI- and ML-driven optimization tools are transforming protein synthesis workflows by enabling predictive modeling, automated design cycles, and real-time reaction adjustments. These technologies significantly reduce development time and enhance the precision of CFPS systems, making them more attractive for high-throughput and industrial-scale applications.
* Increasing Adoption of Reconstituted CFPS Systems
Reconstituted systems — such as PURE (Protein synthesis Using Recombinant Elements) — offer unparalleled control over reaction conditions and components. Their usage is growing rapidly in structural biology, synthetic biology, and nucleic acid research where consistency and reproducibility are critical.
* Expanding Applications Across Research and Biopharma
CFPS has evolved from a niche research tool into a mainstream platform used in:
* Drug discovery and target validation
* Therapeutic protein production
* Rapid prototyping in synthetic biology
* High-throughput screening and automation
* Vaccinology and personalized medicine This expansion significantly contributes to global revenue growth and technological advancement. * Advancements in Automation, Scalability, and Miniaturization
Automation-friendly CFPS kits and instruments now support microfluidic workflows, milliliter-to-liter scale production, and cost-effective parallel processing. These innovations improve throughput, reduce operational burdens, and make CFPS solutions more accessible to academic labs, CROs, and pharmaceutical companies.
Market Opportunities in Cell-free Protein Synthesis
The CFPS landscape presents substantial growth opportunities, particularly in emerging applications such as:
* Vaccine Development & Rapid Response Platforms
Cell-free systems can produce vaccine antigens in hours, making them ideal for pandemic preparedness and on-demand biomanufacturing.
* Synthetic Biology & Bioengineering
CFPS accelerates metabolic pathway engineering, enzyme discovery, biomolecule prototyping, and chassis development for industrial biotechnology.
* Biosensors & Diagnostics
CFPS-powered biosensors enable real-time detection of pathogens, toxins, and biomarkers, opening new avenues in point-of-care diagnostics.
* Personalized Medicine
Emerging CFPS platforms support individualized protein production for personalized treatments, precision diagnostics, and cell-free therapeutics.
* Commercial Validation & Industrial Scale-up
As companies pursue GMP-compliant CFPS systems, commercial applications in therapeutic protein production, gene expression analysis, and enzyme synthesis will expand.
Market Segmentation Insights
By Offering: Products vs. Services
The market is segmented into products (reagents, expression systems, instruments) and services.
CFPS services are projected to grow at the fastest pace due to:
* Expanding outsourcing trends
* Need for specialized expertise and reduced operational costs
* Demand for custom protein expression and scalable project-based solutions
* Adoption among pharma, biotech, academic labs, and diagnostic developers
With rapid project turnaround, minimized infrastructure investment, and access to advanced CFPS technologies, service-based models remain highly attractive for both emerging and established organizations.
By Method: Coupled Tx/Tl vs. Translation-Only Systems
In 2024, coupled transcription-translation (Tx/Tl) dominated the market. Its leading position is driven by:
* Ability to generate proteins directly from DNA templates
* Reduced hands-on time due to combined transcription and translation
* Compatibility with high-throughput applications
* Versatility in producing diverse prokaryotic and eukaryotic proteins
This method is widely used in enzyme engineering, in vitro pathway prototyping, therapeutic screening, and structural biology.
Request Sample Report
Regional Insights: North America Leads, Asia-Pacific Accelerates
North America
North America held the largest market share in 2024 due to:
* Strong biotechnology and synthetic biology ecosystem
* High investment in R&D
* Presence of major CFPS companies
* Robust academic-industry collaborations
* Early adoption of next-generation protein synthesis technologies
Asia-Pacific
The Asia-Pacific region is expected to record the highest growth through 2030, fueled by:
* Government funding for biotechnology and life sciences
* Rapid expansion of pharmaceutical manufacturing
* Growing synthetic biology hubs in China, Japan, South Korea, and India
* Increased adoption of cell-free systems in commercial and academic research
Competitive Landscape: Key Companies Driving Innovation
Major players shaping the global cell-free protein synthesis market include:
* Promega Corporation (US)
* New England Biolabs (US/UK)
* Thermo Fisher Scientific Inc. (US)
* Takara Bio (Japan)
* Genscript (US)
New England Biolabs (NEB)
NEB is a market leader known for its PURExpress reconstituted CFPS systems. Its offerings stand out for:
* Highly controlled reaction environments
* Specialized variants (e.g., ΔRF123) for incorporation and labeling studies
* Reliable, consistent enzyme production
* Strong technical support and global distribution NEB’s consumables-driven business model ensures continuous customer engagement across CFPS workflows.
Thermo Fisher Scientific
Thermo Fisher’s diverse CFPS portfolio includes:
* Bacterial, mammalian, and human lysate systems
* MembraneMax system for membrane protein expression
* Human IVT kits supporting native post-translational modifications The company’s global presence and integrated tools make it a preferred partner in biopharma and academic research.
Promega Corporation
Promega delivers versatile TNT Quick Coupled Systems and an extensive range of prokaryotic and eukaryotic CFPS solutions. Its platforms support:
* High-throughput screening
* Toxic protein expression
* Proteomics and structural biology The company’s accessory reagents, vectors, and templates enhance workflow precision and experimental flexibility.
Conclusion
The Cell-free Protein Synthesis Market is entering a transformative phase as advancements in automation, synthetic biology, and AI-driven protein engineering revolutionize how proteins are designed, produced, and validated. With rising adoption across pharmaceuticals, diagnostics, vaccine development, and academic research, CFPS will continue to play a crucial role in enabling faster discovery cycles, scalable manufacturing, and next-generation biotechnologies.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
